YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Aurobindo Pharma

Aurobindo Pharma

BSE: 524804|NSE: AUROPHARMA|ISIN: INE406A01037|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Nov 26, 16:00
870.50
17.85 (2.09%)
VOLUME 93,439
LIVE
NSE
Nov 26, 16:02
870.70
17.85 (2.09%)
VOLUME 3,653,486
News on Aurobindo Pharma
Select Year: 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Accumulate Aurobindo Pharma; target of Rs 921: Prabhudas Lilladher

1.57 pm | 18 Nov 2020 |  Source: Moneycontrol.com

Prabhudas Lilladher recommended accumulate rating on Aurobindo Pharma with a target price of Rs 921 in its research report dated November 12, 2020....

Pfizer moves US court against Aurobindo Pharma, Dr Reddy's on cancer drug

11.45 am | 17 Nov 2020 |  Source: PTI

Pfizer filed the possiblepatentinfringementpetition against both the companies in the United States District Court for the District of Delaware on two...

Buy Aurobindo Pharma; target of Rs 1025: ICICI Direct

11.22 am | 17 Nov 2020 |  Source: Moneycontrol.com

ICICI Direct is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1025 in its research report dated November 1...

Buy Aurobindo Pharma; target of Rs 980: Motilal Oswal

11.56 am | 15 Nov 2020 |  Source: Moneycontrol.com

Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 980 in its research report dated November 1...

Buy Aurobindo Pharma: target of Rs 1024: Sharekhan

11.31 am | 15 Nov 2020 |  Source: Moneycontrol.com

Sharekhan is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1024 in its research report dated November 12, ...

Aurobindo Pharma says ready to manufacture COVID-19 vaccines for others

1.37 pm | 12 Nov 2020 |  Source: Moneycontrol.com

This will be in addition to its own efforts to develop a vaccine. The company said it is investing Rs 250-Rs 275 crore on a new facility to manufactur...

Aurobindo Pharma shares up 4% after Q2 PAT rises 26% YoY

9.48 am | 12 Nov 2020 |  Source: Moneycontrol.com

Consolidated revenue from operations grew by 15.8 percent year-on-year to Rs 6,483.3 crore with the US formulation business showing a 12.5 percent gro...

Aurobindo Pharma Q2 profit jumps 26% to Rs 805.6 crore; US business grows 12.5%

7.49 pm | 11 Nov 2020 |  Source: Moneycontrol.com

ARV revenue at Rs 502.7 crore increased 111.4 percent YoY and API revenue at Rs 829 crore rose 2.9 percent YoY for the quarter ended September 2020, t...

Buy Aurobindo Pharma; target of Rs 985: Motilal Oswal

1.19 pm | 28 Oct 2020 |  Source: Moneycontrol.com

Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 985 in its research report dated October 26...

Buy Aurobindo Pharma; target of Rs 1025: ICICI Direct

2.00 pm | 27 Oct 2020 |  Source: Moneycontrol.com

ICICI Direct is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1025 in its research report dated October 26...

Aurobindo Pharma share price rises 4% as subsidiary sells business assets

10.34 am | 26 Oct 2020 |  Source: Moneycontrol.com

Jefferies served as the sole financial adviser and Sullivan & Cromwell LLP acted as legal counsel to Aurobindo....

Buy Aurobindo Pharma; target of Rs 1030: Motilal Oswal

11.22 pm | 28 Sep 2020 |  Source: Moneycontrol.com

Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1030 in its research report dated September...

Buy Aurobindo Pharma; target of Rs 975: Sharekhan

12.14 pm | 23 Sep 2020 |  Source: Moneycontrol.com

Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 975 in its research report dated September ...

Aurobindo Pharma: Shot in the arm for Covid vaccine development programme

9.40 am | 16 Sep 2020 |  Source: Moneycontrol.com

Vaccine capacity creation puts Aurobindo in the league of Serum Institute of India and Cadila in the race for a Covid drug...

Buy Aurobindo Pharma; target of Rs 1027: KR Choksey

11.07 am | 19 Aug 2020 |  Source: Moneycontrol.com

KR Choksey is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1027 in its research report dated August 1...

Buy Aurobindo Pharma; target of Rs 1000: Emkay Global Financial

5.06 pm | 17 Aug 2020 |  Source: Moneycontrol.com

Emkay Global Financial is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1000 in its research report da...

Hold Aurobindo Pharma; target of Rs 838: Prabhudas Lilladher

9.08 am | 16 Aug 2020 |  Source: Moneycontrol.com

Prabhudas Lilladher recommended Hold rating on Aurobindo Pharma with a target price of Rs 838 in its research report dated August 13, 2020....

Hold Aurobindo Pharma; target of Rs 975: Sharekhan

7.21 am | 16 Aug 2020 |  Source: Moneycontrol.com

Sharekhan recommended Hold rating on Aurobindo Pharma with a target price of Rs 975 in its research report dated August 13, 2020....

Buy Aurobindo Pharma; target of Rs 1055: Motilal Oswal

7.20 am | 16 Aug 2020 |  Source: Moneycontrol.com

Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1055 in its research report dated August 13...

Buy Aurobindo Pharma; target of Rs 835: Emkay Global Financial

8.50 pm | 07 Jun 2020 |  Source: Moneycontrol.com

Emkay Global Financial is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 835 in its research report dat...

1 2
Quick Links for Aurobindo Pharma
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.